Spexib (Ceritinib) – 150 Mg

Spexib (Ceritinib) – 150 Mg: Uses, Dosage, Side Effects & Complete Guide

A lung cancer diagnosis — particularly one involving a specific genetic mutation — can feel like the ground shifting beneath your feet. But here is something genuinely hopeful: modern oncology has made extraordinary progress in targeting specific genetic drivers of cancer with precision medicines that work more effectively and more safely than traditional chemotherapy alone.

If your oncologist has identified an ALK (Anaplastic Lymphoma Kinase) gene rearrangement in your lung cancer and prescribed Spexib (Ceritinib) – 150 Mg, you are in the world of targeted therapy — a field that has fundamentally transformed outcomes for patients with this type of cancer.

This guide will walk you through everything you need to know about Spexib — what it is, how it works, what to expect during treatment, how to take it correctly, and how to manage side effects — all explained in clear, honest, and human language.

What Is Spexib (Ceritinib) – 150 Mg?

Spexib is a brand name for Ceritinib 150 mg — an oral targeted therapy capsule used in the treatment of ALK-positive non-small cell lung cancer (NSCLC). Each Spexib capsule contains 150 mg of Ceritinib as the active ingredient.

Ceritinib belongs to a class of targeted anticancer drugs called ALK tyrosine kinase inhibitors (ALK TKIs) — medicines specifically designed to block the abnormal ALK protein that drives tumor growth in ALK-rearranged cancers.

Spexib is manufactured as a high-quality generic formulation and is widely prescribed as a cost-effective alternative to the originator brand Zykadia — making this life-extending targeted therapy more accessible to patients who need it.

The standard prescribed dose of Spexib is 450 mg once daily (three 150 mg capsules taken together) — taken with food, which significantly improves tolerability compared to the older fasted dosing regimen at higher doses.

Understanding ALK-Positive Non-Small Cell Lung Cancer

To truly appreciate what Spexib does, it helps to understand the molecular biology behind the cancer it treats.

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Within NSCLC, about 3–7% of cases carry a specific genetic alteration called an ALK gene rearrangement — where the ALK gene fuses with another gene (most commonly EML4), producing an abnormal fusion protein called EML4-ALK.

This abnormal ALK fusion protein is constitutively active — meaning it is permanently switched on, constantly sending signals that tell cancer cells to grow, divide, and survive regardless of normal cellular controls.

Key characteristics of ALK-positive NSCLC:

• More common in younger patients (median age ~50 years)
• More common in non-smokers or light smokers
• Predominantly adenocarcinoma histology
• Has a higher propensity to metastasize to the brain compared to other NSCLC subtypes
• Highly responsive to ALK-targeted therapy — making precise molecular testing before treatment critical

Identifying ALK rearrangement through FISH testing, IHC, or next-generation sequencing (NGS) before starting treatment is essential — Spexib works specifically for ALK-positive tumors and will not be effective in ALK-negative NSCLC.

How Does Spexib (Ceritinib) – 150 Mg Work?

Spexib works through a highly targeted molecular mechanism. Here is the science explained simply:

Step 1 — The Problem: In ALK-positive NSCLC, the EML4-ALK fusion protein acts as a permanently active “on switch” — continuously activating downstream signaling pathways (including PI3K/AKT, RAS/ERK, and JAK/STAT) that drive cancer cell proliferation, survival, and metastasis.

Step 2 — Ceritinib’s Action: Ceritinib binds directly and potently to the ATP-binding site of the ALK kinase domain — the molecular “engine” of the fusion protein. By occupying this site, Ceritinib blocks ATP from binding, which is the energy source the kinase needs to send its growth signals. Without ATP, the kinase cannot function — and all the downstream survival signals it generates are silenced.

Step 3 — The Result: Cancer cells that depend on ALK signaling for survival lose their growth signals. They stop proliferating and undergo apoptosis (programmed cell death). The tumor shrinks or stops growing.

Why Ceritinib Over First-Generation ALK TKI (Crizotinib)? Ceritinib is a second-generation ALK TKI, designed specifically to overcome the most common resistance mutations that develop against Crizotinib — the first ALK TKI to receive approval. Clinical studies showed that Ceritinib retains potent activity against several Crizotinib-resistant ALK mutations, particularly:

• L1196M (gatekeeper mutation)
• G1269A
• S1206Y
• F1174L

Additionally, Ceritinib has demonstrated superior CNS (brain) penetration compared to Crizotinib — critically important given ALK-positive NSCLC’s tendency to spread to the brain.

What Is Spexib (Ceritinib) – 150 Mg Used For?

1. ALK-Positive Metastatic NSCLC — First-Line Treatment

Spexib (Ceritinib) is approved as first-line therapy for patients with ALK-positive metastatic non-small cell lung cancer who have not previously received an ALK inhibitor.

The pivotal ASCEND-4 clinical trial compared Ceritinib to platinum-based chemotherapy as first-line treatment for ALK-positive metastatic NSCLC. Results were striking:

• Ceritinib achieved a median progression-free survival (PFS) of 16.6 months versus 8.1 months with chemotherapy
• Overall response rate (ORR) of 73% with Ceritinib versus 27% with chemotherapy
• Significantly better intracranial disease control — important given ALK+ NSCLC’s brain metastasis tendency

2. ALK-Positive Metastatic NSCLC — Post-Crizotinib (Second-Line)

Spexib is also approved for patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to Crizotinib — the original first-line ALK inhibitor.

The ASCEND-1 and ASCEND-2 trials demonstrated Ceritinib’s robust activity in Crizotinib-pretreated patients — with response rates of 56–72% in patients who had progressed on prior ALK-directed therapy — confirming its role as an effective second-line option.

3. Brain Metastases in ALK-Positive NSCLC

ALK-positive NSCLC has an unusually high rate of CNS metastases — affecting up to 30–40% of patients at some point during their disease course. Spexib demonstrates meaningful intracranial activity — achieving intracranial response rates of approximately 54–60% in patients with brain metastases in clinical trials — making it an important option for patients with CNS involvement.

Spexib (Ceritinib) – 150 Mg Dosage Guide

Getting the dosing right is critical for both safety and effectiveness. Here is a complete overview:

Standard Recommended Dose:

450 mg orally once daily — taken WITH food

This means taking THREE Spexib 150 mg capsules together once a day with a meal.

This 450 mg with-food regimen was established in the ASCEND-8 trial, which demonstrated that 450 mg with food achieved equivalent drug exposure to the older 750 mg fasted regimen — with significantly better gastrointestinal tolerability. This was a major advance in making Ceritinib therapy more manageable for patients.

Treatment Schedule:

• Take once daily, continuously — there is no break period
• Continue until disease progression or unacceptable toxicity
• Treatment is ongoing — not a fixed number of cycles

How to Take Spexib 150 Mg Correctly:

• Take with a meal — this is essential at the 450 mg dose for both absorption and tolerability
• Take at the same time each day — morning with breakfast is a common choice
• Swallow capsules whole with water — do not open, crush, or dissolve
• If you vomit after taking your dose, do not take a replacement dose — resume the next scheduled dose
• If you miss a dose and it is within 12 hours of your scheduled time, take it with food
• If it is less than 12 hours before your next dose, skip the missed dose
• Never double up doses
• Store at room temperature (below 30°C), away from moisture, heat, and direct sunlight

Dose Modifications:

Dose reductions follow a stepwise approach:

• Starting dose: 450 mg daily with food
• First reduction: 300 mg daily with food
• Second reduction: 150 mg daily with food
• Discontinue if unable to tolerate 150 mg

📌 All dose modifications must be directed by your oncologist. Never self-adjust.

Common Side Effects of Spexib (Ceritinib) – 150 Mg

At the 450 mg with-food dose, the gastrointestinal side effects that were historically the biggest challenge with Ceritinib at 750 mg fasted are significantly more manageable. Here is a comprehensive overview:

Very Common Side Effects:

1. Gastrointestinal Effects

• Diarrhea — most commonly reported; usually manageable with dietary modifications and antidiarrheal medications (Loperamide as needed)
• Nausea — generally mild to moderate at the 450 mg with-food dose; antiemetics can help
• Vomiting — less common than with higher fasted dosing; eating a consistent meal before each dose is protective
• Abdominal pain or discomfort — cramping or bloating, typically mild

2. Elevated Liver Enzymes (Hepatotoxicity)

• Elevation of ALT and AST (liver transaminases) is one of the most commonly monitored laboratory abnormalities with Ceritinib
• Usually asymptomatic and detected on blood tests
• Requires regular liver function monitoring throughout treatment

3. Fatigue

• General tiredness is very commonly reported
• Pacing activities and maintaining regular sleep patterns helps

4. Nausea-Related Appetite Decrease

• Reduced appetite, particularly early in treatment
• Eating small, frequent meals and working with a dietitian can help maintain adequate nutrition

5. Hyperglycemia (Elevated Blood Sugar)

• Ceritinib can cause significant increases in blood glucose levels — particularly in patients with pre-existing diabetes or prediabetes
• Regular fasting glucose monitoring is essential
• Patients with diabetes may need adjustments to their antidiabetic medications

6. Elevated Lipase/Amylase (Pancreatitis Risk)

• Laboratory elevation of pancreatic enzymes is commonly observed
• Clinical pancreatitis (abdominal pain, nausea, vomiting) requires immediate evaluation and treatment interruption

7. QTc Interval Prolongation

• Ceritinib can prolong the QT interval on ECG — a heart rhythm change that can (rarely) progress to serious arrhythmia
• Baseline and periodic ECG monitoring is recommended
• Avoid other QT-prolonging medications where possible

Other Common Side Effects:

• Constipation
• Skin rash or itching
• Peripheral edema (swelling of legs/ankles)
• Visual disturbances (blurred vision, flashes)
• Headache
• Weight decrease
• Back pain
• Elevated creatinine (kidney function marker)
• Bradycardia (slow heart rate)

Serious Side Effects (Seek Immediate Medical Attention):

• Interstitial Lung Disease (ILD) / Pneumonitis — new or worsening shortness of breath, dry cough, fever; potentially life-threatening; requires immediate treatment discontinuation; reported in approximately 3–4% of patients
• Severe hepatotoxicity — jaundice, dark urine, severe fatigue, right upper abdominal pain; liver failure rare but reported
• Severe QTc prolongation / Torsades de Pointes — palpitations, dizziness, syncope, irregular heartbeat
• Severe hyperglycemia — excessive thirst, frequent urination, confusion; diabetic ketoacidosis (rare)
• Severe pancreatitis — severe persistent abdominal pain radiating to the back; nausea and fever
• Embryo-fetal toxicity — Spexib is teratogenic; see contraception section

⚠️ Any new shortness of breath or dry cough during Spexib treatment must be reported to your oncologist immediately — it may indicate ILD/pneumonitis, which requires prompt discontinuation.

Who Should NOT Take Spexib (Ceritinib) – 150 Mg?

• Patients whose tumors are ALK-negative — Ceritinib will not be effective without ALK rearrangement
• Patients with known hypersensitivity to Ceritinib or any capsule component
• Patients with severe hepatic impairment — use with caution; limited data; consult specialist
• Patients with congenital long QT syndrome or those taking multiple QT-prolonging medications
• Patients with uncontrolled diabetes — hyperglycemia must be managed before starting
• Pregnant women — Spexib is embryotoxic and teratogenic; can cause fetal harm; reliable contraception is mandatory
• Breastfeeding women — must stop breastfeeding before starting treatment
• Patients with active ILD or severe pulmonary disease — significantly elevated risk of pneumonitis

Important Drug Interactions With Spexib

Ceritinib is primarily metabolized by CYP3A4 and is also a CYP3A4 and CYP2C9 inhibitor — creating clinically significant drug interactions:

📌 Always provide your complete medication list — including supplements, vitamins, and herbal products — to your oncologist and pharmacist before starting Spexib. Never start, stop, or change any medication during Spexib treatment without consulting your oncology team.

Important Monitoring During Spexib Treatment

Your oncology team will schedule regular assessments to ensure treatment safety and effectiveness:

Laboratory Monitoring:

• Liver function tests (ALT, AST, bilirubin) — before starting, then every 2 weeks for the first 3 months, then monthly
• Fasting blood glucose — before starting and periodically throughout; more frequently in diabetic patients
• Serum lipase and amylase — baseline and periodically
• Complete blood count (CBC) — periodically
• Electrolytes (potassium, magnesium) — before starting and periodically (QTc monitoring)
• Renal function (creatinine) — baseline and periodically

Cardiac Monitoring:

• ECG (electrocardiogram) — baseline; repeat if symptoms suggest arrhythmia or if QT-prolonging drugs must be co-administered

Tumor Response Assessment:

• CT scan (chest/abdomen/pelvis) — typically every 8–12 weeks to assess treatment response
• MRI brain — at baseline and periodically given ALK+ NSCLC’s propensity for brain metastases
• Blood tests for ALK resistance mutations (liquid biopsy / ctDNA) may be offered at progression

Resistance to Spexib and Next Steps

Like all targeted therapies, Ceritinib can eventually lose its effectiveness as ALK-positive tumors develop secondary resistance mutations. Common resistance mechanisms include:

• Secondary ALK mutations (e.g., G1202R, I1171T) — the most clinically important
• ALK amplification
• Bypass signaling pathway activation (e.g., EGFR, KRAS, IGF-1R)
• Histological transformation

If resistance develops, your oncologist may recommend:

• Third-generation ALK TKIs — particularly Lorlatinib (Lorbrena), which has the broadest coverage of ALK resistance mutations including G1202R and is now standard treatment after second-generation ALK TKI failure
• Re-biopsy or liquid biopsy to identify the specific resistance mechanism and guide next-line therapy
• Clinical trial enrollment — particularly if standard next-line options have been exhausted

Frequently Asked Questions About Spexib (Ceritinib) – 150 Mg

Q: Why must I take Spexib with food? 

The 450 mg with-food regimen was established in the ASCEND-8 trial and is the currently recommended dosing approach. Taking Spexib with a meal significantly improves its gastrointestinal tolerability — reducing nausea, vomiting, and diarrhea — while achieving equivalent drug exposure compared to the older higher-dose fasted regimen. Food enhances Ceritinib absorption at the 450 mg dose, making it both more effective and better tolerated.

Q: How is Spexib (Ceritinib) different from Crizotinib?

 Crizotinib is the original first-generation ALK inhibitor. Ceritinib (Spexib) is a second-generation ALK TKI that is approximately 20 times more potent than Crizotinib in inhibiting ALK. More importantly, Ceritinib overcomes most Crizotinib resistance mutations, has superior CNS penetration for brain metastasis treatment, and has demonstrated superior progression-free survival compared to Crizotinib in head-to-head studies.

Q: How will I know if Spexib is working? 

Your oncologist will monitor your response through regular CT scans (typically every 8–12 weeks) and clinical assessment. Effective treatment is indicated by tumor shrinkage, stable disease, or resolution of symptoms. Most patients who respond to Ceritinib show measurable tumor reduction within the first 2–3 months of treatment.

Q: Can Spexib treat brain metastases?

 Yes — this is one of Ceritinib’s important advantages. Multiple clinical trials have demonstrated meaningful intracranial response rates with Ceritinib in patients with ALK-positive NSCLC and brain metastases. Its CNS penetration is superior to Crizotinib, though third-generation ALK TKIs like Lorlatinib achieve even greater CNS activity.

Q: What happens when Spexib stops working? 

When disease progresses on Ceritinib, your oncologist will recommend the next appropriate therapy — typically Lorlatinib (a third-generation ALK TKI with the broadest resistance coverage) or a clinical trial. Re-biopsy to characterize the resistance mechanism helps guide the choice of next-line treatment.

Disclaimer:-

This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. Always consult a qualified oncologist or thoracic cancer specialist before starting, stopping, or modifying any cancer treatment, including Spexib (Ceritinib) – 150 Mg.